Use of monoclonal antibodies for the diagnosis and treatment of bladder cancer.
Although the management of cancer by exploiting properties distinguishing neoplastic and normal cells has always been an attractive concept, it was the development of hybridoma technology and the resulting tumor-associated monoclonal antibodies (MAbs) that offered new prospects for this strategy. Twenty years later, some of the applications of MAbs in oncology are now part of the everyday diagnosis and treatment, while others are the subject of intensive investigation. We reviewed the current applications of MAbs in the diagnosis and treatment of bladder cancer and attempted to put the issue into perspective, with particular presentation of their therapeutic potential.
Syrigos
K N
KN
Department of Biochemistry, Imperial College of Science, Technology and Medicine, London, United Kingdom.
Deonarian
D P
DP
Epenetos
A A
AA
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood / Q000652:urine; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D018796:Immunoconjugates / Q000627:therapeutic use; D007150:Immunohistochemistry; D007167:Immunotherapy; D000922:Immunotoxins / Q000627:therapeutic use; D008081:Liposomes; D011355:Prodrugs / Q000627:therapeutic use; D016719:Radioimmunodetection; D016499:Radioimmunotherapy; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy*; D014556:Urine / Q000166:cytology
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D018796:Immunoconjugates; D000922:Immunotoxins; D008081:Liposomes; D011355:Prodrugs